While some biomarkers, such as CSF-based tau and Aβ42/Aβ40 ratio, have received regulatory validation (e.g., FDA-approved assays for Alzheimer’s disease diagnosis), others require further validation through multicenter clinical trials. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.